Erasca up as brain cancer therapy gets FDA's fast track tag

Erasca

01/05/2023 13:40

** Erasca Inc shares  ERAS.O  up 4.7% at $2.89 before the
bell
    ** US FDA grants Fast Track Designation to co's experimental
therapy for the treatment of adult patients with a type of
glioblastoma, brain cancer
    ** FDA's fast track tag is aimed at accelerating development
and review of products intended to treat serious diseases
    ** The therapy, ERAS-801, is undergoing early-stage trial in
patients
    ** As of last close, ERAS down ~36% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))